Informazioni generali
  • Categoria della malattia Altro (BASEC)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Ginevra
    (BASEC)
  • Responsabile dello studio RANAIVOSON Hanta clinical.study@spinevision.com (BASEC)
  • Fonte dati BASEC: Importato da 23.05.2025 ICTRP: N/A
  • Ultimo aggiornamento 23.05.2025 10:56
HumRes63394 | SNCTP000005704 | BASEC2023-D0072

Safety and performance of the Hexanium TLIF system in the treatment of skeletally mature patients with degenerative disc disease – HEXANIUM TLIF Study

  • Categoria della malattia Altro (BASEC)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Ginevra
    (BASEC)
  • Responsabile dello studio RANAIVOSON Hanta clinical.study@spinevision.com (BASEC)
  • Fonte dati BASEC: Importato da 23.05.2025 ICTRP: N/A
  • Ultimo aggiornamento 23.05.2025 10:56

Descrizione riassuntiva dello studio

The objective of this study is to confirm the safety and performance of the Hexanium TLIF system from SPINEVISION in patients with degenerative disc disease. This observational study will collect data on the occurrence of adverse events, as well as the evolution of pain and functional disability, over a period of two years after lumbar fusion surgery with the Hexanium TLIF cage from SPINEVISION.

(BASEC)

Intervento studiato

The surgical technique of "transforaminal lumbar intervertebral fusion" involves the implantation of a medical device (called a cage, here the Hexanium TLIF - SPINEVISION) in place of the defective intervertebral disc, which has been previously removed (partially or entirely); this is done to stabilize one to two segments at the level of the lumbar spine.

(BASEC)

Malattie studiate

Degenerative disc disease is a natural degradation of an intervertebral disc in the spine. This degradation is often the result of natural daily stresses and minor injuries. Degenerative disc disease is typically treated with exercises, medications (pain relievers), and physical therapy. When these standard treatments prove ineffective, lumbar fusion surgery is considered.

(BASEC)

Criteri di partecipazione
1. Patient implanted with / scheduled for implantation with the Hexanium TLIF device: • Patient already implanted with the Hexanium TLIF (implantation date not earlier than July 2021), or • Patient scheduled for implantation with the Hexanium TLIF implant; 2. Patient aged 18 years or older; 3. Patient who has given signed consent or has not opposed the collection of their data, according to local regulations. (BASEC)

Criteri di esclusione
The contraindications are as follows: - a local infection at the surgical site; - signs of local inflammation; - fever or leukocytosis; - morbid obesity; - pregnancy; - pediatric cases or patients whose skeleton is still undergoing general growth; - cases of spondylolisthesis (vertebral slippage) where reduction to grade I is impossible; - a proven or suspected allergy or intolerance to metals; - any case where the selected components for implantation are too large or too small to achieve the desired outcome; - any patient whose tissue coverage of the surgical site is inadequate, or whose bone quality or capital is poor; - any patient for whom the use of an implant would compromise the anatomical structures or expected physiological performance; - a previous arthrodesis at the level to be treated; an arthrodesis is a surgical procedure that involves fusing two or more vertebrae together to treat a back problem; - any case that does not require a bone graft or an arthrodesis; - any presence of an anomaly compromising the normal process of bone remodeling including, but not limited to: severe osteoporosis involving the spine, bone resorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or proven metabolic disorders compromising osteogenesis; - mental disorders; - any patient unwilling to comply with post-operative instructions. (BASEC)

Luogo dello studio

Ginevra

(BASEC)

non disponibile

Sponsor

SPINEVISION SAS Easy Medical Device

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

RANAIVOSON Hanta

+33 1 53 33 25 25

clinical.study@spinevision.com

SPINEVISION SAS

(BASEC)

Informazioni scientifiche

non disponibile

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione d'etica Ginevra

(BASEC)

Data di approvazione del comitato etico

21.11.2023

(BASEC)


ID di studio ICTRP
non disponibile

Titolo ufficiale (approvato dal comitato etico)
Safety and Performance of the Hexanium® TLIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (BASEC)

Titolo accademico
non disponibile

Titolo pubblico
non disponibile

Malattie studiate
non disponibile

Intervento studiato
non disponibile

Tipo di studio
non disponibile

Disegno dello studio
non disponibile

Criteri di inclusione/esclusione
non disponibile

non disponibile

Endpoint primari e secondari
non disponibile

non disponibile

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
non disponibile

ID secondari
non disponibile

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
non disponibile

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile